title: Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
authors.affiliation: University of Arizona Cancer Center.
authors.forename: B G
authors.initials: BG
authors.lastname: Durie
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: C A
authors.initials: CA
authors.lastname: Coltman
authors.forename: R A
authors.initials: RA
authors.lastname: Chapman
authors.forename: S P
authors.initials: SP
authors.lastname: Balcerzk
authors.forename: J D
authors.initials: JD
authors.lastname: Bonnet
authors.forename: D A
authors.initials: DA
authors.lastname: Lipschitz
authors.forename: R L
authors.initials: RL
authors.lastname: Stephens
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000873:Anthracenes / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D014410:Tumor Stem Cell Assay
chemical_list: D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene